Plasma Therapy Market Top Companies, Trends & Growth Factors and Trend Forecast to 2027

Plasma Therapy Market

Platelets, autologous platelets, and cytokines are components of blood plasma that aid in the repair of soft tissues. The traditional practice of plasma therapy is widely utilised in the fields of orthopaedics, dermatology, and dentistry. Additionally, patients with COVID-19 who are hospitalised and at an early stage of their illness may receive convalescent plasma therapy, which contributes to the expansion of the Plasma Therapy Market. Plasma therapy is frequently used for facial rejuvenation, androgenetic alopecia, and wound healing. Plasma is concentrated up to three to five times its physiological value before being injected into the tissues that need to recover.

Increased prevalence of infectious disorders including hepatitis A&B, tetanus, and rabies is anticipated to have a favourable effect on the market throughout the forecast period. Additionally, because of their weakened immunity, the geriatric population is more susceptible to infectious infections as well as other illnesses. This is anticipated to drive the market expansion by raising the need for plasma therapy. The Global Plasma Therapy Market, however, is expected to be constrained by the high cost of plasma therapy. Additionally, an increase in the number of patients with androgenic alopecia and orthopaedic problems creates more prospects for plasma therapy.

Workflows in the healthcare industry have been hampered by the COVID-19 pandemic around the world. Numerous companies, including parts of the healthcare industry, have been forced to temporarily close their doors due to the disease. Additionally, COVID-19 has had a favourable effect on the plasma therapy business. For the treatment of hospitalised COVID-19 disease patients, the FDA granted an emergency use authorization (EUA) for COVID-19 convalescent plasma on August 23, 2020. Additionally, the Houston Methodist Hospital in the United States announced in March 2020 that it had used plasma fractionation in the management of COVID-19. In the fight against the coronavirus illness pandemic, it became the first hospital in the United States to deploy plasma fractionation products.

Another patient who had COVID-19 was treated with plasma from the blood of a patient who had recovered from it. Potentially, convalescent plasma could become a viable medicine to combat the epidemic. Increased demand for immunoglobulins produced from Plasma Therapy Market is expected to fuel the expansion of the plasma fractionation market for immunoglobulin in order to treat COVID-19 patients with autoimmune and inflammatory illnesses.